{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:30:51Z","timestamp":1793374251001,"version":"4.5.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["R01MH81870"],"award-info":[{"award-number":["R01MH81870"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["biologicalpsychiatryjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biological Psychiatry"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.biopsych.2012.05.003","type":"journal-article","created":{"date-parts":[[2012,6,18]],"date-time":"2012-06-18T01:35:29Z","timestamp":1339983329000},"page":"537-547","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":347,"title":["Ketamine for Depression: Where Do We Go from Here?"],"prefix":"10.1016","volume":"72","author":[{"given":"Marije","family":"aan het Rot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Carlos A.","family":"Zarate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis S.","family":"Charney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay J.","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopsych.2012.05.003_bib1","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2012.05.003_bib2","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1038\/sj.npp.1301652","article-title":"Novel drugs and therapeutic targets for severe mood disorders","volume":"33","author":"Mathew","year":"2008","journal-title":"Neuropsychopharmacology"},{"issue":"suppl. 16","key":"10.1016\/j.biopsych.2012.05.003_bib3","first-page":"10","article-title":"The definition and meaning of treatment-resistant depression","volume":"62","author":"Sackeim","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.biopsych.2012.05.003_bib4","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2012.05.003_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/da.10135","article-title":"Intravenous antidepressants: A review","volume":"19","author":"Moukaddam","year":"2004","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.biopsych.2012.05.003_bib6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/13651500410005423","article-title":"Predictors of antidepressant response: A selective review","volume":"8","author":"Dodd","year":"2004","journal-title":"Int J Psychiatry Clin Pract"},{"key":"10.1016\/j.biopsych.2012.05.003_bib7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1176\/jnp.15.1.27","article-title":"Comparison of seizure duration, ictal EEG, and cognitive effects of ketamine and methohexital anesthesia with ECT","volume":"15","author":"Krystal","year":"2003","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.biopsych.2012.05.003_bib8","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.brainresrev.2009.05.005","article-title":"Emerging role of glutamate in the pathophysiology of major depressive disorder","volume":"61","author":"Hashimoto","year":"2009","journal-title":"Brain Res Rev"},{"key":"10.1016\/j.biopsych.2012.05.003_bib9","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1177\/1073858409336093","article-title":"The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders","volume":"15","author":"Machado-Vieira","year":"2009","journal-title":"Neuroscientist"},{"key":"10.1016\/j.biopsych.2012.05.003_bib10","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.tips.2009.09.002","article-title":"Glutamate-based antidepressants: 20 years on","volume":"30","author":"Skolnick","year":"2009","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.biopsych.2012.05.003_bib11","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/clpt.2011.244","article-title":"Ketamine as a novel antidepressant: From synapse to behavior","volume":"91","author":"Murrough","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.biopsych.2012.05.003_bib12","first-page":"460","article-title":"Ketamin ved melankolsk depression","volume":"172","author":"Bjerre","year":"2010","journal-title":"Ugeskr L\u00e6ger"},{"key":"10.1016\/j.biopsych.2012.05.003_bib13","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.biopsych.2010.11.031","article-title":"Dose- and exposure-response to ketamine in depression","volume":"70","author":"Glue","year":"2011","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2012.05.003_bib14","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/archgenpsychiatry.2010.90","article-title":"A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression","volume":"67","author":"DiazGranados","year":"2010","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2012.05.003_bib15","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.biopsych.2011.12.010","article-title":"Replication of ketamine's antidepressant efficacy in bipolar depression: A randomized controlled add-on trial","volume":"71","author":"Zarate","year":"2012","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2012.05.003_bib16","doi-asserted-by":"crossref","first-page":"234","DOI":"10.4414\/smw.2007.11852","article-title":"Intravenous ketamine therapy in a patient with a treatment-resistant major depression","volume":"137","author":"Liebrenz","year":"2007","journal-title":"Swiss Med Weekly"},{"key":"10.1016\/j.biopsych.2012.05.003_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15622970701420481","article-title":"Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression","volume":"10","author":"Liebrenz","year":"2009","journal-title":"World J Biol Psychiatry"},{"issue":"suppl 13","key":"10.1016\/j.biopsych.2012.05.003_bib18","first-page":"23","article-title":"When at first you don't succeed: Sequential strategies for antidepressant nonresponders","volume":"58","author":"Thase","year":"1997","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.biopsych.2012.05.003_bib19","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/15622970701714370","article-title":"Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: Report of two cases","volume":"10","author":"Paul","year":"2009","journal-title":"World J Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2012.05.003_bib20","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1176\/appi.ajp.2011.11010128","article-title":"Monitoring ketamine treatment response in a depressed patient via peripheral mammalian target of rapamycin activation","volume":"168","author":"Denk","year":"2011","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2012.05.003_bib21","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1526-4637.2006.00101.x","article-title":"Two case studies of patients with major depressive disorder given low-dose (subanesthetic) ketamine infusions","volume":"7","author":"Correll","year":"2006","journal-title":"Pain Med"},{"key":"10.1016\/j.biopsych.2012.05.003_bib22","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.biopsych.2008.09.029","article-title":"Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist","volume":"65","author":"Phelps","year":"2009","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2012.05.003_bib23","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.4088\/JCP.08m04659","article-title":"Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist","volume":"70","author":"Machado-Vieira","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.biopsych.2012.05.003_bib24","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4088\/JCP.09m05327blu","article-title":"Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder","volume":"71","author":"DiazGranados","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.biopsych.2012.05.003_bib25","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.pnpbp.2011.03.019","article-title":"Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression","volume":"35","author":"Ibrahim","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2012.05.003_bib26","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/npp.2011.338","article-title":"Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: Results from a 4-week, double-blind, placebo-controlled study","volume":"37","author":"Ibrahim","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2012.05.003_bib27","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/npp.2010.24","article-title":"Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine","volume":"35","author":"Salvadore","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2012.05.003_bib28","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.biopsych.2008.08.014","article-title":"Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine","volume":"65","author":"Salvadore","year":"2009","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2012.05.003_bib29","article-title":"An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression","author":"Salvadore","year":"2011","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.biopsych.2012.05.003_bib30","series-title":"Evidence-Based Medicine: How to Practice and Teach EBM","author":"Sackett","year":"2000"},{"key":"10.1016\/j.biopsych.2012.05.003_bib31","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.pscychresns.2010.10.009","article-title":"The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS","volume":"191","author":"Valentine","year":"2011","journal-title":"Psychiatry Res Neuroimaging"},{"key":"10.1016\/j.biopsych.2012.05.003_bib32","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1017\/S1461145709000169","article-title":"Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: A pilot randomized, placebo-controlled continuation trial","volume":"13","author":"Mathew","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.biopsych.2012.05.003_bib33","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.biopsych.2009.08.038","article-title":"Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression","volume":"67","author":"aan het Rot","year":"2010","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2012.05.003_bib34","doi-asserted-by":"crossref","first-page":"414","DOI":"10.4088\/JCP.10l06447blu","article-title":"A case of sustained remission following an acute course of ketamine in treatment-resistant depression","volume":"72","author":"Murrough","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.biopsych.2012.05.003_bib35","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/01.yct.0000263257.44539.23","article-title":"Rapid relief of severe major depressive disorder by use of preoperative ketamine and electroconvulsive therapy","volume":"23","author":"Goforth","year":"2007","journal-title":"J ECT"},{"issue":"suppl 8","key":"10.1016\/j.biopsych.2012.05.003_bib36","first-page":"17","article-title":"Prevalence and management of treatment-resistant depression","volume":"68","author":"Nemeroff","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.biopsych.2012.05.003_bib37","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jad.2008.10.014","article-title":"What happens to patients with treatment-resistant depression?","volume":"116","author":"Fekadu","year":"2009","journal-title":"J Affect Disord"},{"key":"10.1016\/j.biopsych.2012.05.003_bib38","article-title":"Antidepressants versus placebo for depression in primary care","volume":"3","author":"Arroll","year":"2009","journal-title":"Cochrane Database of Syst Rev"},{"key":"10.1016\/j.biopsych.2012.05.003_bib39","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1176\/appi.ajp.161.1.171","article-title":"An open-label trial of riluzole in patients with treatment-resistant major depression","volume":"161","author":"Zarate","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2012.05.003_bib40","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.biopsych.2004.11.023","article-title":"An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression","volume":"57","author":"Zarate","year":"2005","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2012.05.003_bib41","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.biopsych.2006.08.037","article-title":"Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms","volume":"61","author":"Sanacora","year":"2007","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2012.05.003_bib42","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.pain.2003.07.001","article-title":"Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study","volume":"108","author":"Carr","year":"2004","journal-title":"Pain"},{"key":"10.1016\/j.biopsych.2012.05.003_bib43","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.biopsych.2011.02.018","article-title":"Reply to: Dose- and exposure-response to ketamine in depression","volume":"70","author":"Murrough","year":"2010","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2012.05.003_bib44","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.biopsych.2009.04.029","article-title":"Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression","volume":"66","author":"Price","year":"2009","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2012.05.003_bib45","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1017\/S1461145711000629","article-title":"A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department","volume":"14","author":"Larkin","year":"2011","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.biopsych.2012.05.003_bib46","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/YCT.0b013e3181c3b0aa","article-title":"Rapid antidepressant effect of ketamine anesthesia during electroconvulsive therapy of treatment-resistant depression: Comparing ketamine and propofol anesthesia","volume":"26","author":"Okamoto","year":"2010","journal-title":"J ECT"},{"key":"10.1016\/j.biopsych.2012.05.003_bib47","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00406-011-0205-7","article-title":"Clinically favourable effects of ketamine as an anaesthetic for electroconvulsive therapy: A retrospective study","volume":"261","author":"Kranaster","year":"2011","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.biopsych.2012.05.003_bib48","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0893-133X(98)00067-0","article-title":"Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis","volume":"20","author":"Newcomer","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2012.05.003_bib49","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1360-0443.2009.02761.x","article-title":"Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: A 1-year longitudinal study","volume":"105","author":"Morgan","year":"2010","journal-title":"Addiction"},{"key":"10.1016\/j.biopsych.2012.05.003_bib50","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/01.YCT.0000264384.29516.18","article-title":"Synergistic antidepressant effects with ketamine and ECT","volume":"25","author":"Loo","year":"2009","journal-title":"J ECT"},{"key":"10.1016\/j.biopsych.2012.05.003_bib51","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.neuropharm.2011.08.044","article-title":"Signaling pathways underlying the rapid antidepressant actions of ketamine","volume":"62","author":"Duman","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopsych.2012.05.003_bib52","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jpsychires.2006.09.009","article-title":"Role of BDNF in bipolar and unipolar disorder: Clinical and theoretical implications","volume":"41","author":"Post","year":"2007","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.biopsych.2012.05.003_bib53","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.pnpbp.2011.05.010","article-title":"The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder","volume":"35","author":"Jernigan","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2012.05.003_bib54","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1190287","article-title":"mTOR-Dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists","volume":"329","author":"Li","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.biopsych.2012.05.003_bib55","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1177\/0269881111405359","article-title":"Lack of effect of ketamine on cortical glutamate and glutamine in healthy volunteers: A proton magnetic resonance spectroscopy study","volume":"26","author":"Taylor","year":"2012","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.biopsych.2012.05.003_bib56","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature10130","article-title":"NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses","volume":"475","author":"Autry","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.biopsych.2012.05.003_bib57","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1345\/aph.1Q371","article-title":"Intravenous ketamine for treatment-resistant major depressive disorder","volume":"46","author":"Covvey","year":"2012","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.biopsych.2012.05.003_bib58","first-page":"170","article-title":"Ketamine followed by memantine for the treatment of major depressions","volume":"42","author":"Kollmar","year":"2008","journal-title":"Aust N Z J Psychiatry"},{"key":"10.1016\/j.biopsych.2012.05.003_bib59","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1089\/jpm.2008.9828","article-title":"Intravenous ketamine \u201cburst\u201d for refractory depression in a patient with advanced cancer","volume":"11","author":"Stefanczyk-Sapieha","year":"2008","journal-title":"J Palliative Med"},{"key":"10.1016\/j.biopsych.2012.05.003_bib60","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1176\/jnp.2010.22.4.442","article-title":"The use of a series of ketamine infusions in two patients with treatment-resistant depression","volume":"22","author":"Messer","year":"2010","journal-title":"J Neuropsychiatry Clin Neurosci"}],"container-title":["Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322312004179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322312004179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T14:56:54Z","timestamp":1757775414000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006322312004179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":60,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S0006322312004179"],"URL":"https:\/\/doi.org\/10.1016\/j.biopsych.2012.05.003","relation":{},"ISSN":["0006-3223"],"issn-type":[{"value":"0006-3223","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ketamine for Depression: Where Do We Go from Here?","name":"articletitle","label":"Article Title"},{"value":"Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopsych.2012.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}